Calypte Only Company with Full Menu of Tests.

euch bald auch nicht mehr. aber caly kann ja nichts vernünftiges bringen.

auch 2006 wird es keine großaufträge geben. aber das schreibe ich euch ja mehrfach jedes jahr, einige glauben es immer noch nicht...muhahhaahahahaha

Time & Sales most recent  next page
Rec. Time Action Price Volume
12:00:50 PM Ask 0.22  102600  
12:00:46 PM Ask 0.22  100600  
11:59:08 AM Ask 0.22  102600  
11:58:58 AM Ask 0.22  100600  
11:57:20 AM Ask 0.22  102600  
11:57:10 AM Ask 0.22  100600  
11:55:28 AM Ask 0.22  102600  
11:55:24 AM Ask 0.22  100600  
11:53:40 AM Ask 0.22  102600  
11:53:36 AM Ask 0.22  100600  
11:52:56 AM Bid 0.21  42500  
11:52:52 AM Trade 0.21  11000  
11:52:10 AM Bid 0.21  53500  
11:52:02 AM Trade 0.21  700  
11:52:02 AM Trade 0.21  200  
11:52:02 AM Trade 0.21  400  
11:52:02 AM Trade 0.21  700  
11:52:02 AM Trade 0.21  100  
11:52:02 AM Trade 0.21  100  
11:51:58 AM Trade 0.21  300  
11:51:32 AM Trade 0.21  400  
11:46:42 AM Ask 0.22  102600  
11:46:36 AM Ask 0.22  100600  
11:44:52 AM Ask 0.22  102600  

 

ich habe beruflich mit kranken Menschen zu tun.
Die haben wirklich Probleme in ihrem Leben.
Du machst dir Probleme wirklich krank bist du.
Lass dir helfen und das meine ich ernsthaft.
Grüße Lucky  

ein brokersince, gelle?

Die neuesten Bewertungen, die für Postings von LuckyStrike vergeben wurden   mehr... >>  

Punkte   Bewerter  Betreff  Bewertungszeit  Postingzeit  
    Kade_I    Jetzt langs ,Joelu du bist nur noch krank  25.04.06 22:10  25.04.06 19:52  


du wirst die wahrheit lesen müssen kade, besser du schaust nicht mehr hier herein.



lucky: hilf dir erst mal selber, bevor du anderen helfen willst. deine realitätsverweigerung ist doch nicht mehr normal. wie gesagt, wenn gale selber dir sagen würde, dass er dich bescheißt, du würdest es nicht glauben...


lucky, probleme hier sind nichtig. nur müsst ihr eben damit leben, dass echo für euer verhalten zu ertragen. das können eben die meisten nicht. kade schonmal gar nicht. kritikfähigkeit war für ihn schon immer ein fremdwort.  

paar fakten?


eure charttechnik:


Support/Resistance
Type Value Conf.
resist. 0.29 2
resist. 0.28 12
resist. 0.25 8
resist. 0.24 3
resist. 0.23 2
resist. 0.22 8
resist. 0.21 5
resist. 0.20 2
resist. 0.20 14
supp 0.19 24
supp 0.18 2
supp 0.18 20
supp 0.17 14
supp 0.16 46
 

Time & Sales  
Price Size    Exch Time
0.20 549300    AMX 18:11:13
0.199 5000    NLS 17:16:12
0.199 5000    NLS 16:15:09
0.199 5000    NLS 16:15:09
0.20 1200    AMX 16:00:13
0.20 7400    NLS 15:59:57
0.19 112000    AMX 15:59:28
0.19 2700    NLS 15:59:22
0.19 10000    NLS 15:59:22
0.19 5000    NLS 15:59:22
0.19 67000    NLS 15:59:16
0.19 21000    NLS 15:59:16
0.19 9000    NLS 15:59:05
0.19 50000    NLS 15:59:02
0.19 2000    NLS 15:58:23
0.20 800    NLS 15:58:11
0.19 4000    NSX 15:57:59
0.20 50000    NLS 15:57:45
0.20 800    NLS 15:57:17
0.20 3000    NLS 15:55:05
0.20 10000    NLS 15:42:20
0.20 700    NSX 15:42:09
0.20 5000    NSX 15:40:36
0.19 5000    NSX 15:29:40
0.19 200    NLS 15:27:38
0.19 700    NLS 15:27:38
0.19 100    NLS 15:27:38
0.19 300    NLS 15:27:38
0.19 10100    NLS 15:27:38
0.19 100    PAC 15:27:37

durchschnittshandelskurs: 0.1991$  

Support/Resistance
Type Value Conf.
resist. 0.29 2
resist. 0.28 12
resist. 0.25 8
resist. 0.24 3
resist. 0.23 2
resist. 0.22 7
resist. 0.21 5
resist. 0.20 2
resist. 0.20 11
supp 0.19 24
supp 0.18 2
supp 0.18 18
supp 0.17 14
supp 0.16 46
 

Time & Sales
Price Size Exch Time
0.20 195300 AMX 17:45:29
0.20 1800 AMX 16:02:18
0.19 12500 AMX 15:59:45
0.19 7200 AMX 15:58:40
0.19 1500 NLS 15:58:31
0.19 7400 AMX 15:55:18
0.19 50000 NLS 15:55:08
0.20 6000 AMX 15:50:10
0.20 500 NLS 15:48:17
0.20 1500 NSX 15:47:25
0.20 400 NLS 15:38:56
0.20 4500 NLS 14:46:31
0.19 7200 AMX 14:46:03
0.19 100 NLS 14:45:56
0.19 1000 NLS 14:45:56
0.19 2800 NLS 14:45:56
0.19 200 NLS 14:45:56
0.19 266500 NLS 14:45:56
0.19 7000 NLS 14:45:56
0.19 5500 NLS 14:45:56
0.19 5500 PAC 14:45:56
0.19 4200 NLS 14:45:56
0.20 10000 NLS 14:28:55
0.20 10000 NLS 14:24:43
0.19 4400 NLS 14:04:11
0.19 10000 NLS 13:52:27
0.20 900 NLS 13:48:19
0.19 4000 AMX 13:48:15
0.19 2000 PAC 12:41:33
0.19 100 PAC 12:41:33
 

Time & Sales
Price Size Exch Time
0.19 675600 AMX 18:26:33
0.195 3500 NLS 15:58:54
0.19 400 NSX 15:52:59
0.19 10000 NLS 15:49:32
0.19 6000 NSX 15:49:02
0.19 4000 NSX 15:47:23
0.18 10000 NLS 15:46:06
0.183 6200 NLS 15:38:15
0.181 12800 NLS 15:38:15
0.19 10000 AMX 15:36:26
0.19 600 AMX 15:33:58
0.19 5800 NLS 15:33:49
0.19 5000 NLS 15:32:32
0.19 5000 AMX 15:32:30
0.19 5000 AMX 15:32:06
0.19 2500 AMX 15:31:31
0.19 2700 NLS 15:28:37
0.19 2000 NLS 15:28:28
0.19 2000 AMX 15:28:20
0.19 1500 PAC 15:28:13
0.19 100 PAC 15:28:13
0.19 100 PAC 15:28:13
0.19 6100 AMX 15:28:12
0.19 800 NLS 15:28:05
0.19 400 NLS 15:28:04
0.19 2000 NLS 15:28:04
0.19 100 NLS 15:28:04
0.19 1200 NLS 15:28:04
0.19 4700 NLS 15:26:51
0.19 1600 AMX 15:26:51
 

Support/Resistance
Type Value Conf.
resist. 0.29 2
resist. 0.28 12
resist. 0.25 8
resist. 0.24 3
resist. 0.23 2
resist. 0.22 7
resist. 0.21 4
resist. 0.20 2
resist. 0.20 10
resist. 0.19 24
supp 0.18 2
supp 0.18 16
supp 0.17 14
supp 0.16 46  

 

schiff verlassen. zurückbleiben die gutgläubigen, die hier die zeche zahlen. langsam müsste es doch der letzte depp begriffen haben, welches linke spiel hier gespielt wird.

mann oh mann oh mann ...

eure kurse von heute: RT´s :

Time & Sales most recent  next page
Rec. Time Action Price Volume
12:59:14 PM Trade 0.1909 4000
12:38:56 PM Trade 0.19 800
12:28:20 PM Trade 0.19 700
12:27:52 PM Bid 0.19 159100
12:27:52 PM Trade 0.19 1000
12:27:36 PM Ask 0.2 280000
12:19:58 PM Bid 0.19 160100
12:15:58 PM Trade 0.19 2000
12:15:58 PM Bid 0.19 152600
12:14:22 PM Ask 0.2 281000
12:09:06 PM Ask 0.2 283000
12:07:18 PM Trade 0.1927 600
11:59:52 AM Bid 0.19 154600
11:59:32 AM Ask 0.2 273000
11:56:20 AM Ask 0.2 268000
11:54:16 AM Bid 0.19 152600
11:25:58 AM Ask 0.2 258000
11:23:46 AM Bid 0.19 128600
11:23:30 AM Bid 0.19 134300
11:13:46 AM Trade 0.2 2100
11:10:14 AM Ask 0.2 248000
11:03:18 AM Ask 0.2 247500
11:01:22 AM Trade 0.2 500
11:00:16 AM Bid 0.19 128600
10:58:28 AM Ask 0.2 245500
10:56:20 AM Bid 0.19 98600
10:56:10 AM Ask 0.2 244500
10:56:10 AM Trade 0.2 30000
10:44:24 AM Trade 0.19 35000
10:44:24 AM Bid 0.19 68600
10:35:26 AM Ask 0.2 256000
10:33:08 AM Bid 0.19 103600
10:29:42 AM Bid 0.19 93600
10:29:42 AM Trade 0.19 100
10:28:32 AM Ask 0.2 291000
10:22:32 AM Ask 0.2 272000
10:22:32 AM Trade 0.19 200
10:22:28 AM Bid 0.19 93700
10:19:20 AM Trade 0.19 2000
10:17:44 AM Trade 0.19 5000
10:15:20 AM Ask 0.2 260000
10:11:34 AM Trade 0.19 10000
10:11:32 AM Bid 0.19 93900
10:06:36 AM Trade 0.19 50000
10:06:34 AM Bid 0.19 103900
10:00:20 AM Ask 0.2 274500
9:47:56 AM Ask 0.2 269500
9:41:28 AM Ask 0.2 263500
9:36:02 AM Trade 0.19 5000
9:35:58 AM Bid 0.19 153900  

 

Calypte Appoints Roger I. Gale as President and CEO



LAKE OSWEGO, Ore., May 8 /PRNewswire-FirstCall/ -- Calypte Biomedical Corporation (Amex: HIV) (the "Company"), medical diagnostic tests manufacturer for the professional point of care (PRO) and over the counter (OTC) segments of the market primarily for the detection of antibodies to the human immunodeficiency virus (HIV), announced today that Mr. Roger I. Gale, Chairman of the Board since November 2004, has been appointed President and Chief Executive Officer. Mr. Gale will relocate to the Company's corporate offices in Portland, Oregon.

He has held the position of interim CEO since October 2005. Mr. Gale will dedicate his full attention to Calypte and has concurrently resigned his position as Executive Chairman of WaveCrest Group Enterprises Limited ("WaveCrest"), an International Communications Services Provider.

Mr. Gale is one of two Directors originally appointed to Calypte's Board pursuant to an August 2003 agreement between the Company and Marr Technologies BV ("Marr"), the Company's largest stockholder and strategic/joint venture partner. He brings not only the knowledge of Calypte he has gained over the past one and a half years, but also his proven effectiveness in building and maintaining the company's strategic relationship with Marr.

Mr. Gale commented, "I am honored to lead the Company at this critical juncture. As Chairman, I have directed Calypte's transition from a lab-based diagnostic company to a lean, point of care diagnostic testing company. We are entering new markets in both the professional sectors and, for the first time, the Over-the-Counter or OTC markets. We now have approvals in parts of Africa, Southeast Asia and the Middle East, and are expanding that reach on a steady basis. We have worked hard to position ourselves in China, which is currently the largest potential market for HIV/AIDS testing. Marr has been a strong partner for us in China, and is not only assisting us in monitoring the Chinese FDA approval process, which we expect to conclude this year, but has already assisted us in establishing a sales and marketing plan for our Joint Venture to take full advantage of the vast opportunities that China has to offer."

Mr. Gale continued, "As we continue to implement our strategy for China, we have the opportunity to monetize the multi-million dollar investment that we have made in intellectual property rights. We have begun the initial steps to launch what will ultimately be an HIV-1/2 OTC OMT (Oral Fluid) test in the U.S., as well as a line of other diagnostic tests that detect a variety of other Sexually Transmitted Diseases. We are also seeking to secure a facility in the Portland area in which we would bring together the staff in our R&D and corporate headquarters, adding manufacturing capability for these new products. We expect to bring this facility on line with the objective of initiating the U.S. FDA approval process by year-end -- without any disruption to our current international plans.

Mr. Gale's background includes considerable international experience. Since October 2001, Mr. Gale has served as Executive Chairman of the Board of Directors of WaveCrest. From 1999 to 2001, he was Chairman and co-founder of End2End Wireless Limited, a UK wireless access services provider. From 1996 to 1998 he was Chief Executive of the OPIC-guaranteed AIG-Brunswick Millennium Fund based in Russia. In addition, he has held senior positions with the Asian Development Bank (ADB, Manila) and the International Finance Corporation (IFC), the private sector arm of the World Bank in Washington, D.C. He serves as a Director and as Chairman of the Audit Committee of Mechel Steel Group, (NYSE: MTL). Mr. Gale holds a Master of Economics degree from the University of New England, Australia, and a Higher National Diploma from the Royal Agricultural College, Cirencester, England.

The Company will release its first quarter 2006 financial results on May 15, 2006 and will schedule a conference call at that time.

About Calypte Biomedical:

Calypte Biomedical Corporation is a U.S.-based healthcare company focused on the development and commercialization of diagnostic testing products for the detection of sexually transmitted diseases such as the HIV-1 BED Incidence EIA and new diagnostic test products for the rapid detection of HIV and other sexually transmitted diseases, several of which do not require blood samples. Calypte believes there is a significant need for rapid detection of such diseases globally to control their proliferation, particularly in developing countries, which lack the medical infrastructure to support laboratory-based testing. Calypte believes that testing for HIV and other sexually transmitted infectious diseases may make important contributions to public health, and could increase the likelihood of treating those with undetected HIV and other sexually transmitted diseases.

Statements in this press release that are not historical facts are forward-looking statements within the meaning of the Securities Act of 1933, as amended. Those statements include statements regarding the intent, belief or current expectations of the Company and its management. Such statements reflect management's current views, are based on certain assumptions and involve risks and uncertainties. Actual results, events, or performance may differ materially from the above forward-looking statements due to a number of important factors, and will be dependent upon a variety of factors, including, but not limited to, the Company's ability to obtain additional financing, if and as needed, and access funds from its existing financing arrangements that will allow it to continue its current and future operations and whether demand for its test products in domestic and international markets will generate sufficient revenues to achieve positive cash flow and profitability. The Company undertakes no obligation to publicly update these forward-looking statements to reflect events or circumstances that occur after the date hereof or to reflect any change in the Company's expectations with regard to these forward-looking statements or the occurrence of unanticipated events. Factors that may impact the Company's success are more fully disclosed in the Company's most recent public filings with the U.S. Securities and Exchange Commission ("SEC"), including its annual report on Form 10-KSB for the year ended December 31, 2005 and its subsequent filings with the SEC.


   Company Contact:                         Investor Relations Contact:
   Theodore R Gwin,                         Tim Clemensen,
    Chief Financial Officer                 Rubenstein Investor Relations
   (971) 204-0282                           Phone: (212) 843-9337
   email:tgwin@calypte.com                  email:tclemensen@rubensteinir.com


SOURCE  Calypte Biomedical Corporation
   -0-                             05/08/2006
   /CONTACT:  Theodore R Gwin, Chief Financial Officer of Calypte Biomedical
Corporation, +1-971-204-0282, tgwin@calypte.com; or Investor Relations: Tim
Clemensen of Rubenstein Investor Relations, +1-212-843-9337,
tclemensen@rubensteinir.com, for Calypte Biomedical Corporation/
   /Web site:  http://www.calypte.com /
   (HIV)

CO:  Calypte Biomedical Corporation, WaveCrest Group Enterprises Limited,
    Mechel Steel Group
ST:  Oregon
IN:  BIO HEA IDC MTC
SU:  PER

BR
-- NYM015 --
0692 05/08/200607:30 EDThttp://www.prnewswire.com
 

 

http://phx.corporate-ir.net/...MueG1sP2lwYWdlPTQxNjc4MDQmcmVwbz10ZW5r



 

Calypte Announces First Quarter Results
LAKE OSWEGO, Ore., May 16 /PRNewswire-FirstCall/ -- Calypte Biomedical Corporation (Amex: HIV) today announced its financial results for the quarter ended March 31, 2006.

For the quarter ended March 31, 2006, Calypte recorded revenues of $91,000, compared with revenue of $39,000 in the first quarter in 2005. The net loss for the first quarter of 2006 was approximately $3.4 million or $0.018 per common share compared with a net loss of $3.3 million or $0.019 per common share for the three months ended March 31, 2005. Net loss for the quarter includes non-cash interest expense of $1.7 million in 2006 and $0.2 million in 2005.

Calypte's urine EIA, serum Western Blot and urine Western Blot HIV-1 in vitro diagnostic test business (the "Legacy Business") has been treated as a "discontinued operation" for financial reporting purposes. The 2005 revenues reported above exclude the sales from the Legacy Business. The 2005 net loss reported above, however, includes losses of $0.9 million attributable to the Legacy Business. There were no revenues or costs associated with the Legacy Business in 2006.

Roger I. Gale, Chairman and newly-appointed Chief Executive Officer, and Calypte's management will host a conference call on Thursday, May 18, 2006 at 4:30 PM Eastern Time to discuss the Company's first quarter financial results and current operations.

The call can be accessed in the U.S. by dialing 800-599-9816 and outside of the U.S. by dialing 617-847-8705. The participant pass code is 35249624. The conference call will also be Web cast live at http://www.calypte.com. An audio replay of the call will be available for 30 days, beginning approximately 1 hour after the conference call ends, by dialing 888-286-8010 in the U.S., or 617-801-6888 from outside of the U.S. The account code for the playback is 60707345. The Web cast will also be available for replay on the company's website.


 

wo sind die pusher, lucky-strike unde brokersince alias ottomanrosendahl etc??? schon die tan-liste gezückt unf verkauft? oder wird das deasaster wie seit jahren wieder bis  zu den nächsten q-zahlen wieder ausgesessen?

also kurz und bündig, für alle träumer und realitätsverweigerer:

umsätze in q-1: 91.000 lachenlachen

nettoverlust der lfd. geschäfte: 3.407.000$ lachenlachenlachen

cash nur noch 239.000$ zu 492.000$ ende 2005 lachenlachen

aktienzahl "nur": 192,822,970 zum 11.05.

glückwunsch, da kommt was großes!!!! das große abkotzen.


aber klar, wir halten trotz eines sinkenden kurses weiter und hoffen auf die nächsten q-zahlen. alle 3 monate das böse erwachen, aber manche lernen es nie weinenweinenweinen  

ist (bis auf die aktienzahl) sogar NOCH schlechter, als meine erwartungen....

ich habe mich mal wieder vertan...breites Grinsenaufmerksamweinen  

euren zulassungen?

euren großaufträgen???

ich sage es euch: N I C H T S!!!

daran wird auch die chinazulassung nichts ändern, die garantiert noch dieses quartal kommen wird. auch dadurch wird es KEINE großaufträge geben.

3.400.000 verlust bei einem umsatrz von 91.000!!! ich glaube ihr habt zu heiß gebadet!!! wer das noch akzeptiert, dem ist nicht mehr zu helfen.

verlust in höhe vom 37,36-fachen der mini-umsatz!!!!

so schlecht ward ihr seit jahren nicht mehr. da war caly vor 3-4 jahren aber besser aufgestellt.

junge, junge, junge...aber iohr werdet es immer noch nicht glauben, was ich euch seid jahr und tag erzähle, gelle...äh...GALE (eurem parade-board-vorsitzendem zu ehren)
 

eine mk von 192,822,970 x 0,18$ = 34.708.134$!!!


wofür????????????? dafür das der verlust das ca. 37-fache des kaum vorhandenen umsatzes beträgt?

eine mk von ca. 5.000.000 halte ich im grunde noch für übertrieben, bei den zahlen. was meint ihr, wieviel neue aktien caly ausgeben wird, um zu überleben, um die cash-quote zu bedienen?

kurs bei einem mk von 5.000.000 wäre 0,0259$. da werdet ihr auch hinlaufen...wohl auch noch drunter.

das amex-listing ist ohnehin weg. keine chance bei den zahlen.

der rS kommt ende des jahres. gleubt es oder lasst es  

Time & Sales
Price Size Exch Time
0.18 434900 AMX 17:53:41
0.18 1000 AMX 16:00:05
0.19 800 AMX 15:59:37
0.19 100 PAC 15:59:28
0.19 2000 NDD 15:44:30
0.19 500 AMX 15:41:14
0.19 100 PAC 15:41:13
0.19 100 PAC 15:41:13
0.19 100 AMX 15:39:59
0.19 100 AMX 15:38:21
0.19 200 AMX 15:35:16
0.19 200 AMX 15:34:00
0.19 100 AMX 15:31:04
0.19 100 AMX 15:29:44
0.19 100 AMX 15:26:38
0.19 100 AMX 15:25:15
0.19 100 AMX 15:23:11
0.19 100 AMX 15:21:07
0.19 100 AMX 15:18:00
0.19 200 AMX 15:13:39
0.19 100 AMX 15:10:17
0.19 100 AMX 15:06:42
0.19 100 AMX 15:04:29
0.19 100 NDD 15:01:29
0.19 100 AMX 15:01:29
0.19 1700 PAC 14:59:07
0.19 100 PAC 14:59:07
0.19 100 PAC 14:59:07
0.19 9800 PAC 14:59:07
0.19 15100 PAC 14:57:28

durchschnittshandelskurs: 0.1881$  

Support/Resistance
Type Value Conf.
resist. 0.29 2
resist. 0.28 12
resist. 0.25 8
resist. 0.24 2
resist. 0.23 3
resist. 0.22 7
resist. 0.21 2
resist. 0.20 2
resist. 0.20 16
resist. 0.19 32
resist. 0.18 2
resist. 0.18 14
supp 0.17 14
supp 0.16 42  

Time & Sales  
Price Size    Exch Time
0.18 45600    AMX 18:24:54
0.18 600    AMX 15:59:00
0.18 12400    NDD 15:58:54
0.18 100    NDD 15:55:11
0.18 1500    NDD 15:53:18
0.18 400    NDD 15:53:18
0.18 100    NDD 15:51:58
0.18 100    NDD 15:51:58
0.19 2000    PAC 15:51:02
0.19 600    PAC 15:50:55
0.19 100    PAC 15:50:55
0.19 100    PAC 15:50:55
0.19 1000    AMX 15:50:51
0.18 100    NDD 15:50:35
0.18 100    NDD 15:44:04
0.18 100    NDD 15:35:09
0.18 1500    AMX 15:34:05
0.18 200    PAC 15:28:06
0.18 100    NDD 15:28:06
0.18 100    NDD 15:28:06
0.18 7000    AMX 15:27:26
0.18 100    NDD 15:26:34
0.18 100    PAC 15:26:34
0.18 100    NDD 15:26:34
0.18 3000    NDD 15:24:15
0.19 3300    AMX 15:21:40
0.18 100    NDD 15:21:04
0.18 200    NDD 15:21:04
0.18 300    PAC 15:21:04
0.18 100    NDD 15:20:14

durchschnittshandelskurs: 0.1863$  

Support/Resistance
Type Value Conf.
resist. 0.29 2
resist. 0.28 12
resist. 0.25 8
resist. 0.24 2
resist. 0.23 3
resist. 0.22 7
resist. 0.21 2
resist. 0.20 2
resist. 0.20 20
resist. 0.19 30
resist. 0.18 2
resist. 0.18 16
supp 0.17 22
supp 0.16 38
 

schweigen, werden denken: da habe ich dem alten joelu doch über jahre unrecht getan. hätte ich nicht besser mal eher auf ihn gehört und nicht den pushern hier im board geglaubt, die mich in den dreck zogen...


zu spät...aber womöglich kommt eure ausstiegschance noch einmal, bevor das amex-listing wegf ist. nämlich dann, wenn calys produkte definitv in china zum verkauf zugelassen werden, werden sie wieder wie die fliegen in das teil hineinfliegen, aber dann am fliegenfänger hängen bleiben...